To discuss the limitations of current RSV vaccine strategies and propose a new framework for vaccine design that incorporates computational methods and structural biology.
Approach:
Key Findings:
RSV is a major cause of severe lower respiratory tract disease in infants and older adults.
Current vaccines based on the F protein have limited efficacy due to antigenic instability and viral evolution.
The preF conformation of the F protein is crucial for exposing neutralizing epitopes.
Recent advances in structural biology and computational protein design have improved stabilization of preF conformations.
Emerging methods like protein language models enable antigen design guided by sequence-structure relationships.
The G protein contributes to immune evasion through glycan shielding and CX3C-mediated immunomodulation.
Current vaccine approaches based on a single stabilized conformation do not fully address antigenic drift.
Existing vaccines have previously resulted in vaccine-associated enhanced respiratory disease (VAERD).
Interpretation:
The integration of computational strategies with structural biology can lead to more effective RSV vaccines by addressing antigenic variability.
Limitations:
Current vaccine approaches based on a single stabilized conformation do not fully address antigenic drift.
Existing vaccines have previously resulted in vaccine-associated enhanced respiratory disease (VAERD).
Conclusion:
The proposed Rational Design 2.0 framework may provide a conceptual basis for future RSV vaccine development strategies.
Amoxicillin-clavulanate was not linked to lower treatment failure but was associated with a slightly higher risk of secondary infections compared with amoxicillin in adults with uncomplicated acute sinusitis.
